Effects of clozapine on auditory event-related potentials in schizophrenia

Biological Psychiatry

Volumn 44, Issue 8, 1998, Pages 716-725

  Umbricht, Daniel ^a,b   Javitt, Daniel ^b,c   Novak, Gerald ^b   Bates, John ^b   Pollack, Simcha ^b,d   Lieberman, Jeffrey ^e   Kane, John ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d ST JOHN'S UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotics; Clozapine; Event related potentials; Mismatch negativity; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; FEMALE; HALOPERIDOL; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032532181     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00524-6     Document Type: Article

References (41)

1. Andreasen N.C. Negative symptoms in schizophrenia Definition and reliability . Arch Gen Psychiatry. 39:1982;784-788.
2. Blackwood D.H.R., Whalley L.J., Christie J.E., Blackburn I.M., St. Clair D.M., McInnes A. Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry. 150:1987;154-160.
3. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfeldt A., et al. Effects of clozapine on positive and negative symptoms in outpatient with schizophrenia. Am J Psychiatry. 151:1994;20-26.
4. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 36:1994;717-725.
5. Catts S.V., Shelley A., Ward P.B., Liebert B., McConaghy N., Andrews S., et al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry. 152:1995;213-219.
6. Duncan C.C., Morihisa J., Fawcett R.W., Kirch D.G. P300 in schizophrenia State or trait marker? Psychopharmacol Bull. 23:1987;497-501.
7. Egan M.F., Duncan C.C., Suddath R.L., Kirch D.G., Mirsky A.F., Wyatt R.J. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr Res. 11:1994;259-271.
8. Eikmeier G., Lodeman E., Zerbin D., Gastpar M. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia A preliminary report . Biol Psychiatry. 31:1992;1065-1069.
9. Ford J.M., White P.M., Csernansky J.G., Faustman W.O., Roth W.T., Pfefferbaum A. ERPs in schizophrenia Effects of antipsychotic medication . Biol Psychiatry. 36:1994;153-170.
10. Ford J.M., White P.M., Lim K.O., Pfefferbaum A. Schizophrenics have fewer and smaller P300s A single-trial analysis . Biol Psychiatry. 35:1994;96-103.
11. Gold J.M., Harvey P.D. Cognitive deficits in schizophrenia. Psychiatr Clin Am. 16:1993;295-312.
12. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 162:1993;43-48.
13. Goldman R.S., Bates J.A., Bilder R.M., Kane J., Schooler N.R., Marder S. The effects of clozapine and haloperidol on memory functioning in treatment refractory schizophrenics. Schizophr Res. 18:1996;221.
14. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 153:1996;321-330.
15. Guy W. EDCEU Assessment Manual. 1976;217-222 US Department of Health, Education and Welfare, 1976, Rockville, Md.
16. Hagger C., Buckley P., Kenny J.T., Friedman L., Uboby D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712.
17. Hoff A.L., Faustman W.O., Wienecke M., Espinoza S., Costa M., Wolkowitz O., et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
18. Javitt D.C., Doneshka P., Zylberman I., Ritter W., Vaughan H.G. Impairment of early cortical processing in schizophrenia An event-related potential confirmation study . Biol Psychiatry. 33:1993;513-519.
19. Javitt D.C., Doneshka P., Grochowski S., Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry. 52:1995;550-558.
20. Johnson R. Jr. A triarchic model of P300 amplitude. Psychophysiology. 23:1986;367-384.
21. Kane J.M., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine . Arch Gen Psychiatry. 45:1988;789-896.
22. Kane M.M., Schooler N.R., Marder S., Wirshing W., Ames D., Umbricht D., et al. Efficacy of clozapine versus haloperidol in a long-term clinical trial. Schizophr Res. 18:1996;127.
23. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 55:(suppl B):1994;82-87.
24. McCarley R.W., Faux S.F., Shenton M.E., Nestor P.G., Adams J. Event-related potentials in schizophrenia Their biological and clinical correlates and a new model of schizophrenic pathophysiology . Schizophr Res. 4:1991;209-231.
25. McCarley R.W., Shenton M.E., O'Donnell B.F., Faux S.F., Kikinis R., Nestor P.G., et al. Auditory P300 abnormalities and left posterior superior temporal gyrus volume reduction in schizophrenia. Arch Gen Psychiatry. 50:1993;190-197.
26. Näätänen R. The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav Brain Sci. 13:1990;201-288.
27. Novak G.P., Ritter W., Vaughan H.G. Jr, Wiznitzer M.L. Differentiation of negative event-related potentials in an auditory discrimination task. Electroencephalogr Clin Neurophysiol. 75:1990;255-275.
28. Oades R.D., Zerbin D., Eggers C. Stimulus-Vergleichsprozesse bei psychotischen Jugendlichen mit paranoiden and nicht paranoiden Symptomen "Mismatch Negativity" deutet auf differenzierte Beeinträchtigung hin . Bauman P. Biologische Psychiatrie der Gegenwart. 1993;69-74 Springer-Verlag, Vienna.
29. O'Donnell B.F., Shenton M.E., McCarley R.W., Faux S.F., Smith R.S., Salisbury D.F., et al. The auditory N2 component in schizophrenia Relationship to MRI temporal lobe gray matter and to other ERP abnormalities . Biol Psychiatry. 34:1993;26-40.
30. Polich J., Kok A. Cognitive and biological determinants of P300 An integrative review . Biol Psychol. 41:1995;103-146.
31. Pritchard W.S. Cognitive event-related potential correlates of schizophrenia. Psychol Bull. 100:1986;43-66.
32. Ritter W., Simson R., Vaughan H.G. Jr, Friedman D. A brain event related to the making of a sensory discrimination. Science. 203:1979;1358-1361.
33. Ritter W., Simson R., Vaughan H.G. Jr. Event-related potential correlates of two stages of information processing in physical and semantic discrimination tasks. Psychophysiology. 20:1983;168-179.
34. Ritter W., Paavilainen P., Lavikainen J., Reinikainen K., Alho K., Sams M., et al. Event-related potentials to repetition and change of auditory stimuli. Electroencephalogr Clin Neurophysiol. 83:1992;306-321.
35. Sams M., Paavilainen P., Alho K., Naatanen R. Auditory frequency discrimination and event-related potentials. Electroencephalogr Clin Neurophysiol. 62:1985;437-448.
36. Schall U., Catts S.V., Chaturvedi S., Redenbach J., Karayanidis F., Ward P.B. The effect of clozapine therapy on psychometric and event-related potential (ERP) measures of cognitive dysfunction in schizophrenia. Schizophr Res. 15:1995;164.
37. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., McConaghy N. Mismatch negativity An index of a preattentive processing deficit in schizophrenia . Biol Psychiatry. 30:1991;1059-1062.
38. Spitzer R.I., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R-Patient Version. 1990;American Psychiatric Press, Washington, DC.
39. Williams R., Baillie P., Dickson R.A., Dalby J.T. Cognitive and behavioral efficacy of clozapine in clinical trials. Can J Psychiatry. 38:1993;522.
40. Woerner M.G., Mannuzza S., Kane J.M. Anchoring the Brief Psychiatric Rating Scale An aid to improve reliability . Psychopharmacol Bull. 24:1988;112-117.
41. Zahn T.P., Pickar D., Haier R.J. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophr Res. 13:1994;133-144.